Merriman Curhan Ford upgrades Catalyst Pharmaceuticals (Nasdaq: CPRX) from Sell to Neutral.

Merriman analyst says, "The hope of developing a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE